Health Catalyst
HCAT
159 hedge funds and large institutions have $423M invested in Health Catalyst in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 49 reducing their positions, and 25 closing their positions.
4,933% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $463K
30% more capital invested
Capital invested by funds: $326M → $423M (+$97.5M)
8% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 49
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.29% less ownership
Funds ownership: 86.34% → 86.05% (-0.29%)
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
1% less funds holding
Funds holding: 161 → 159 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Nepsis Inc
Minneapolis,
Minnesota
|
+$6.15M |
| 2 |
FAM
Fred Alger Management
New York
|
+$6.09M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.8M |
| 4 |
Impax Asset Management Group
London,
United Kingdom
|
+$2.6M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$5.44M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.98M |
| 3 |
Millennium Management
New York
|
-$4.96M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$2.23M |
| 5 |
Goldman Sachs
New York
|
-$1.92M |
HCAT Hedge Fund Activity: Q3 2024 in Review
159 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Health Catalyst (HCAT) for Q3 2024, worth a combined $423M — up 30% from $326M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of HCAT and 24 opened new positions — a net loss of 1 holder — while 49 trimmed existing stakes and 53 added.
The largest buyer was Nepsis Inc, adding an estimated $6.15M. The largest seller was Invenomic Capital Management, exiting entirely with an estimated $5.44M sold.
- 159 institutional investors held Health Catalyst (HCAT) as of Q3 2024, down from 161 in Q2 2024.
- Funds reported $423M of Health Catalyst stock for Q3 2024, up 30% quarter-over-quarter.
- 24 funds opened new Health Catalyst positions in Q3 2024 and 25 closed out, a net change of -1 holder.
- The largest Health Catalyst buyer in Q3 2024 was Nepsis Inc, an estimated $6.15M added.
- The largest Health Catalyst seller in Q3 2024 was Invenomic Capital Management, an estimated $5.44M sold.
Based on aggregated 13F filings for Q3 2024.